Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSIW) Revenue (2022 - 2025)

TriSalus Life Sciences' Revenue history spans 4 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, Revenue rose 59.85% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $45.2 million, up 53.41%, while the annual FY2025 figure was $45.2 million, 53.41% up from the prior year.
  • Revenue reached $13.2 million in Q4 2025 per TLSIW's latest filing, up from $11.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $13.2 million in Q4 2025 to a low of $3.0 million in Q1 2023.
  • Average Revenue over 4 years is $7.2 million, with a median of $6.9 million recorded in 2024.
  • Peak YoY movement for Revenue: soared 32.37% in 2023, then soared 116.39% in 2024.
  • A 4-year view of Revenue shows it stood at $3.2 million in 2022, then soared by 77.34% to $5.7 million in 2023, then skyrocketed by 44.4% to $8.3 million in 2024, then soared by 59.85% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Revenue are $13.2 million (Q4 2025), $11.6 million (Q3 2025), and $11.2 million (Q2 2025).